0000950142-24-001490.txt : 20240530
0000950142-24-001490.hdr.sgml : 20240530
20240530180952
ACCESSION NUMBER: 0000950142-24-001490
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240529
FILED AS OF DATE: 20240530
DATE AS OF CHANGE: 20240530
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eckelman Brendan P.
CENTRAL INDEX KEY: 0001766433
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42031
FILM NUMBER: 241006989
MAIL ADDRESS:
STREET 1: C/O INHIBRX, INC.
STREET 2: 11025 N. TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inhibrx Biosciences, Inc.
CENTRAL INDEX KEY: 0002007919
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 990613523
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 795-4220
MAIL ADDRESS:
STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: Ibex SpinCo, Inc.
DATE OF NAME CHANGE: 20240111
4
1
es240484860_4-eckelman.xml
OWNERSHIP DOCUMENT
X0508
4
2024-05-29
0
0002007919
Inhibrx Biosciences, Inc.
INXB
0001766433
Eckelman Brendan P.
C/O INHIBRX BIOSCIENCES, INC.
11025 NORTH TORREY PINES ROAD, SUITE 140
LA JOLLA
CA
92037
0
1
0
0
Chief Scientific Officer
0
Common Stock
2024-05-29
4
A
0
433888
A
433888
I
By the Eckelman Living Trust Dated February 5, 2014
Common Stock
2024-05-29
4
A
0
40000
A
40000
I
By trust
Common Stock
2024-05-29
4
A
0
40000
A
40000
I
By trust
Stock Option (right to buy)
15.86
2024-05-30
4
A
0
175000
0.00
A
2034-05-30
Common Stock
175000
175000
D
The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.
These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014.
These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.
These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.
This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
/s/ Kelly D. Deck, Chief Financial Officer of Inhibrx Biosciences, Inc., as attorney-in-fact
2024-05-30